1400W 2HCl

Catalog No.S8337 Synonyms: N-(3-(Aminomethyl)benzyl)acetamidine

For research use only.

1400W (N-(3-(Aminomethyl)benzyl)acetamidine) is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase(iNOS).

1400W 2HCl Chemical Structure

CAS No. 214358-33-5

Selleck's 1400W 2HCl has been cited by 8 Publications

Purity & Quality Control

Choose Selective NOS Inhibitors

Biological Activity

Description 1400W (N-(3-(Aminomethyl)benzyl)acetamidine) is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase(iNOS).
Targets
iNOS [1]
(Cell-free assay)
nNOS [1]
(Cell-free assay)
eNOS [1]
(Cell-free assay)
<7 nM(Kd) 2 μM(Ki) 50 μM(Ki)
In vitro

1400W is either an irreversible inhibitor or an extremely slowly reversible inhibitor of human iNOS. Inhibition of human iNOS by 1400W is time-dependent. 1400W is competitive with L-arginine. 1400W is not a substrate for iNOS[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
RAW264.7 NGrvS5JCdnSraX7mcIFudWG2b4L5JIF{e2G7 MW[yOEBpenN? NEnLVJpCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJHJCXzJ4ND63JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgcol1emmlIH;4bYRmKHC{b3T1Z5Rqd25iYX\0[ZIhOjRiaILzJIJ6KEe{aXXzd{Bie3OjeTygTWM2OD1yLkNOwG0> NI\X[Wg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzNlE1QCd-MkOyN|IyPDh:L3G+
RAW264.7 M1XJOmFvfGmrbn\sZY1u[XSxcomgZZN{[Xl? MoDRNlAhcHK| Mn3kRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDh[4FqdnO2IFzQV{1{fGmvdXzheIVlKG2xdYPlJHJCXzJ4ND63JINmdGy|IHHzd4V{e2WmIHHzJI5qfHKrdHWgZYNkfW23bHH0bY9vKGGodHXyJFIxKGi{czDifUBndHWxcnnt[ZRzgSxiSVO1NF0xNjQQvF2= M{TWclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzNke4OlU1Lz5zMU[3PFY2PDxxYU6=
RAW264.7 NYjNXYk1TnWwY4Tpc44h[XO|YYm= NWC3NnNWUW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBvcXS{aXOgc5hq\GViZ3Xu[ZJifGmxbjDpckBud3W|ZTDSRXczPjRwNzDj[YxteyCycnX0doVifGWmIEGgbJIh[mWob4LlJGxRWyClaHHscIVv\2ViYomgS5Jq\XO|IH3leIhw\CxiSVO1NF0yNjYQvF2= MkDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{N{i4OVQoRjF7Mke4PFU1RC:jPh?=
N9 NUHDd4ZjTnWwY4Tpc44h[XO|YYm= NUDOelFPUW6qaXLpeI9zgSCnZn\lZ5Qhd2ZiY3;tdI92dmRib36geIhmKGGlY4XteYxifGmxbjDv[kBPVzJiaX6geIhmKGO3bIT1doUhdWWmaXGgc4YhVjliY3XscJMhcW5icnXzdI9ve2VidH:gUHBUN0mITj3nZY1u[SxiSVO1NF0zNjMQvF2= M33te|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MEGzNFEzLz5zNUCxN|AyOjxxYU6=
RAW264.7 MlvtRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? MWLBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJGxRWy2|dHnteYxifGWmIH3veZNmKFKDV{K2OE44KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gcol1emmlIH;4bYRmKHC{b3T1Z5Rqd25icILleJJm[XSnZDCxJIhzKGKnZn;y[UBNWFNiY3jhcIxmdmenLDDJR|UxRTJwM988US=> MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjZ4MkGwNUc,OTJ4NkKxNFE9N2F-
RAW264.7 NYDvOZhPTnWwY4Tpc44h[XO|YYm= MWDJcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIH7peJJq[yCxeHnk[UBi[2O3bYXsZZRqd25iaX6gcY92e2ViUlHXNlY1NjdiY3XscJMtKEmFNUC9Nk44|ryP NV;RTFhtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2PVkxQTdpPkG5Olk6ODl5PD;hQi=>
RAW264.7 NFH3OVNCdnSraX7mcIFudWG2b4L5JIF{e2G7 MV[yOEBpenN? NYj4T|ZJSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIGLBW|I3PC55IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhVFCVLXnu[JVk\WRibnn0dol1\SCjY3P1cZVt[XSrb36gZYZ1\XJiMkSgbJJ{NCCLQ{WwQVIvQc7:TR?= MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTV4OEe2OEc,OTV3Nki3OlQ9N2F-
RAW264.7 MkLiRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? M4W2WlI1KGi{cx?= NFfESnlCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKEySUz3zeIlufWyjdHXkJI1wfXOnIGLBW|I3PC55IHPlcIx{KGG|c3Xzd4VlKGG|IHXm[oVkfCCxbjDOU{Bxem:mdXP0bY9vKHC{ZYTy[YF1\WRiMTDodkBj\W[xcnWgUHBUKGOqYXzs[Y5o\SCvZXHzeZJm\CCjZoTldkAzPCCqcoOsJGlEPTB;Mz6x{txO NVPhd3B4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG5NFg6QDRpPkGxPVA5QTh2PD;hQi=>
N9 NWf0S5c6SW62aXnu[oxidW2jdH;yfUBie3OjeR?= NFnqbnVCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKEySUz;JSm4u\2GvbXGtd5RqdXWuYYTl[EBud3W|ZTDOPUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIH7peJJq[yCxeHnk[UBxem:mdXP0bY9vKHC{ZYTy[YF1\WRiMTDodkBj\W[xcnWgUHBUN0mITnfhcY1iKGOqYXzs[Y5o\SxiSVO1NF0{NjcQvF2= M{fPXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{Nk[yNVAyLz5zMk[2NlExOTxxYU6=
RAW264.7 MkLTSpVv[3Srb36gZZN{[Xl? NFjXXHlKdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIHnuJI1wfXOnIGLBW|I3PC55IHPlcIx{NCCLQ{WwQVMvPzkQvF2= NGq3XoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m4PFg4PCd-MUe5PFg5PzR:L3G+
RAW 264 MX;GeY5kfGmxbjDhd5NigQ>? M4\He|I1KGi{cx?= MoTSTY5pcWKrdHnvckBw\iBzdXevcYwhVFCVLYP0bY12dGG2ZXSgcol1cXKlIH;4bYRmKGGlY4XteYxifGmxbjDpckBTSVdiMk[0JINmdGy|IHHmeIVzKDJ2IHjyd{whUUN3ME21MlLPxE1? NE[2XJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{OyNFI1Pid-MUezNlAzPDZ:L3G+
RAW264.7 MYTGeY5kfGmxbjDhd5NigQ>? NWD6cG1uUW6qaXLpeI9zgSCnZn\lZ5Qhd2ZiY3;tdI92dmRib36geIhmKGGlY4XteYxifGmxbjDv[kBPVzJiaX6geIhmKGO3bIT1doUhdWWmaXGgc4YhWkGZIEK2OE44KGOnbHzzJIlvKHKnc4DvcpNmKHSxIFzQV{whUUN3ME22MlHPxE1? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTBzM{CxNkc,OTVyMUOwNVI9N2F-
N9 MWnBcpRqcW6obHHtcYF1d3K7IHHzd4F6 Mm\6NlQhcHK| NWqwXJM2SW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIF65JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTM2lHVi2pYX3tZU1qdmS3Y3XkJI5qfHKrdHWgZYNkfW23bHH0bY9vKGGodHXyJFI1KGi{czygTWM2OD14LkROwG0> NXfMRm5zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW1Olg4PjRpPkG1OVY5PzZ2PD;hQi=>
RAW264.7 M4fWW2N6fG:2b4jpZ4l1gSCjc4PhfS=> MWGyOEBpenN? NF\VfWlEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB{NDDodpMh[nliTWTTJIF{e2G7LDDJR|UxRTR5LkS3{txO M1fXUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkOyNVQ5Lz5{M{KzNlE1QDxxYU6=
RAW264.7 MVPBcpRqcW6obHHtcYF1d3K7IHHzd4F6 MWC1NEB2VQ>? NHfyW28zPCCqcoO= MV3BcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJI1wfXOnIGLBW|I3PC55IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhVFCVLXnu[JVk\WRibnn0dol1\SCycn;keYN1cW:wIHH0JFUxKHWPIITy[YF1\WRiM{CgcYlveyCkZX\vdoUhVFCVIHPoZYxt\W6pZTDt[YF{fXKnZDDh[pRmeiB{NDDodpMh[nliR4Lp[ZN{KG2ndHjv[C=> MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR2N{e0NUc,OjB2NEe3OFE9N2F-
RAW264.7 Mn71RY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? MmmyNE42KHSxIEKgeW0> MX:yJIhzew>? NX73dVdmSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJGNQYC1{IHX4dJJme3Orb36gZZQhOC53IITvJFIhfU1iaX7jeYJifGWmIH\vdkAzKGi{czDwdolweiC2bzDMVHMh[2ijbHzlcodmKG2nYYP1doVlKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NF\xN3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzNlE1QCd-MkOyN|IyPDh:L3G+
RAW264.7 NFTUUGZCdnSraX7mcIFudWG2b4L5JIF{e2G7 M{XONFIhfU1? NUP2dG81OiCqcoO= NG[5UIlCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJHJCXzJ4ND63JINmdGy|IHHzd4V{e2WmIHHzJIRwf26{ZXf1cIF1cW:wIH;mJGxRWy2rbnT1Z4VlKGmQT2OgcXJPSSCneIDy[ZN{cW:wIHH0JFIhfU1iaX7jeYJifGWmIH\vdkAzKGi{czDwdolweiC2bzDMVHMh[2ijbHzlcodmKG2nYYP1doVlKGGodHXyJFkhcHK|IHL5JHJVNVCFUjDhcoFtgXOrcx?= M4myUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkOyNVQ5Lz5{M{KzNlE1QDxxYU6=
RAW264.7 MYfBcpRqcW6obHHtcYF1d3K7IHHzd4F6 MU[wMlUhfG9iMjD1US=> NH;Vd4wzKGi{cx?= NUnzb2Z3SW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJIlPV1NiZYjwdoV{e2mxbjDheEAxNjVidH:gNkB2VSCrbnP1ZoF1\WRiZn;yJFIhcHK|IIDybY9zKHSxIFzQV{BkcGGubHXu[4UhdWWjc4Xy[YQh[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NEnLeJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzNlE1QCd-MkOyN|IyPDh:L3G+
RAW264.7 MnriSpVv[3Srb36gZZN{[Xl? M4S0U|QhfU1? NFraOndKdmirYnn0bY9vKGmQT2OgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCrbjDMVHMucW6mdXPl[EBud3W|ZTDSRXczPjRwNzDj[YxteyCjdDC0JJVOKGK7IGLUMXBEWiCjbnHsfZNqew>? NIfF[pM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W0NlMxPid-Mke1OFI{ODZ:L3G+
RAW264.7 MV7GeY5kfGmxbjDhd5NigQ>? NX\5[G1kPCC3TR?= MknlTY5pcWKrdHnvckBqVk:VIIDyc5RmcW5iZYjwdoV{e2mxbjDs[ZZmdHNiaX6gUHBUNWmwZIXj[YQhdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYSgOEB2VSCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NHu3XW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W0NlMxPid-Mke1OFI{ODZ:L3G+
In vivo 1400W selectively prevents microvasculature injury in rats. 1400W is greater than 50-fold more potent against iNOS than eNOS in a rat model of endotoxin-induced vascular injury. Moreover, 1400W also dose-dependently reduces LPS-induced vascular leakage associated with iNOS induction in the colon, lung, liver, kidney, and heart. The maximal protection is close to 100% for all organs except the kidney (kidney:54%)[1]. 1400W has an ameliorative effect on both oxidative and nitrosative stress in the kidneys against renal I/R injury in rats[2]. Treatment with 1400W can reduce the rate of growth of solid tumors in mice[4].

Protocol (from reference)

Cell Research:[3]
  • Cell lines: RAW264.7 cells
  • Concentrations: 100 μM
  • Incubation Time: 16 h
  • Method: RAW264.7 cells are treated with LPS/IFNγ for 16 h and GAPDH-p300 binding is abolished by the iNOS inhibitor 1400W (100 μM). Cell lysates are immunoprecipitated with an anti-p300 antibody and the immunoprecipitates are analysed by western blotting with an anti-GAPDH antibody.
Animal Research:[1]
  • Animal Models: Rats
  • Dosages: 0.1-10 mg/kg
  • Administration: s.c.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 250.17
Formula

C10H15N3.2HCl

CAS No. 214358-33-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(=NCC1=CC=CC(=C1)CN)N.Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00845169 Completed Procedure: Forearm vascular study Endothelial Dysfunction University of Edinburgh|NHS Lothian|Umeå University April 2012 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy 1400W 2HCl | 1400W 2HCl supplier | purchase 1400W 2HCl | 1400W 2HCl cost | 1400W 2HCl manufacturer | order 1400W 2HCl | 1400W 2HCl distributor